Current News

Contact | Print version | Send article | RSS feed

Archemix and Merck KGaA to Collaborate on Aptamer-Based Cancer Therapeutics

19 Jan 2007 - Archemix Corp. announced that it has signed a multi-year, multi-target agreement with Merck KGaA, that focuses on the discovery, development, and commercialization of first-in-class aptamer-based therapeutics to treat cancer.
 
Under terms of the agreement, Archemix will receive an upfront payment and committed research funding of as much as $10 million. Archemix also could receive milestones and royalty payments for products successfully commercialized under the collaboration. In addition, Archemix may participate in the co-promotion of products that result from the collaboration. Other financial terms were not disclosed.
 
"Archemix is the leader in the field of aptamers, a new class of drugs that has tremendous potential in the battle against cancer," said Dr. Bernhard Kirschbaum, Executive Senior Vice President and Director of Research for Merck Serono. "We hope this collaboration will further our efforts to provide physicians and oncology patients with innovative, targeted cancer treatments."